APA (7th ed.) Citation

M, P., GN, H., M, C., KI, P., F, L., Y, I., . . . J, B. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2†. Annals of oncology : official journal of the European Society for Medical Oncology, 25(12), 2357. https://doi.org/10.1093/annonc/mdu456

Chicago Style (17th ed.) Citation

M, Piccart, et al. "Everolimus Plus Exemestane for Hormone-receptor-positive, Human Epidermal Growth Factor Receptor-2-negative Advanced Breast Cancer: Overall Survival Results from BOLERO-2†." Annals of Oncology : Official Journal of the European Society for Medical Oncology 25, no. 12 (2014): 2357. https://doi.org/10.1093/annonc/mdu456.

MLA (9th ed.) Citation

M, Piccart, et al. "Everolimus Plus Exemestane for Hormone-receptor-positive, Human Epidermal Growth Factor Receptor-2-negative Advanced Breast Cancer: Overall Survival Results from BOLERO-2†." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 25, no. 12, 2014, p. 2357, https://doi.org/10.1093/annonc/mdu456.